Skip to main content
Hero image
*Limitations apply. Valid only for those with private insurance. Program provides up to $16,000 annually for the cost of COSENTYX and up to $150 per infusion (up to $1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.

IGA, Investigator's Global Assessment; IL, interleukin; PASI, Psoriasis Area and Severity Index.

1. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.
2. Langley RG et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338. doi:10.1056/ NEJMoa1314258
3. Bagel et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). Dermatol Ther (Heidelb). 2018;8(4):571-579.
doi: 10.1007/s13555-018-0265-ym
4. Data on file. CAIN457A2326 Week 16 Analysis. Novartis Pharmaceuticals Corp; January 2018. 
5. Stelara. Prescribing information. Janssen Biotech, Inc. 
6. Bissonnette R et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507-1514. doi:10.1111/jdv.14878
7. Data on file. CAIN457A2304E1 Clinical Study Report. Novartis Pharmaceuticals Corp; February 2018.